title: Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.
abstract: Normalization of blood glucose is essential for the prevention of diabetes mellitus (DM)-related microvascular and macrovascular complications. Despite substantial literature to support the benefits of glucose lowering and clear treatment targets, glycemic control remains suboptimal for most people with DM in the United States. Pharmacokinetic limitations of conventional insulins have been a barrier to achieving treatment targets secondary to adverse effects such as hypoglycemia and weight gain. Recombinant DNA technology has allowed modification of the insulin molecule to produce insulin analogues that overcome these pharmacokinetic limitations. With time action profiles that more closely mimic physiologic insulin secretion, rapid acting insulin analogues (RAAs) reduce post-prandial glucose excursions and hypoglycemia when compared to regular human insulin (RHI). Insulin glulisine (Apidra) is a rapid-acting insulin analogue created by substituting lysine for asparagine at position B3 and glutamic acid for lysine at position B29 on the B chain of human insulin. The quick absorption of insulin glulisine more closely reproduces physiologic first-phase insulin secretion and its rapid acting profile is maintained across patient subtypes. Clinical trials have demonstrated comparable or greater efficacy of insulin glulisine versus insulin lispro or RHI, respectively. Efficacy is maintained even when insulin glulisine is administered post-meal. In addition, glulisine appears to have a more rapid time action profile compared with insulin lispro across various body mass indexes (BMIs). The safety and tolerability profile of insulin glulisine is also comparable to that of insulin lispro or RHI in type 1 or 2 DM and it has been shown to be as safe and effective when used in a continuous subcutaneous insulin infusion (CSII). In summary, insulin glulisine is a safe, effective, and well tolerated rapid-acting insulin analogue across all BMIs and a worthy option for prandial glucose control in type 1 or 2 DM.
authors: Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver and Health Sciences Center, Denver, CO 80232, USA. heather.ulrich@uchsc.edu
authors: Heather
authors: H
authors: Ulrich
authors: Benjamin
authors: B
authors: Snyder
authors: Satish K
authors: SK
authors: Garg
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; C479079:insulin glulisine
references: N Engl J Med. 1993 Sep 30;329(14):977-86
references: 8366922
references: N Engl J Med. 2005 Dec 22;353(25):2643-53
references: 16371630
references: Diabetes Care. 2005 Sep;28(9):2100-5
references: 16123473
references: Lancet. 1998 Sep 12;352(9131):837-53
references: 9742976
references: Endocr Pract. 2005 Jan-Feb;11(1):11-7
references: 16033730
references: Horm Metab Res. 2006 Jun;38(6):429-33
references: 16823727
references: Diabetes Res Clin Pract. 1999 Feb;43(2):137-42
references: 10221666
references: Arch Intern Med. 2005 Jun 27;165(12):1337-44
references: 15983281
references: Diabetes Care. 2003 Mar;26(3):881-5
references: 12610053
references: Expert Opin Pharmacother. 2005 Apr;6(4):643-51
references: 15934890
references: Diabetes Care. 2004 Oct;27(10):2363-8
references: 15451901
references: Diabet Med. 1999 May;16(5):384-7
references: 10342337
references: Diabetes Care. 1998 Nov;21(11):1904-9
references: 9802741
references: Diabetes. 1997 Feb;46(2):265-70
references: 9000704
references: Endocr Pract. 2004 Mar-Apr;10 Suppl 2:63-70
references: 15251643
references: Int J Toxicol. 2006 Jan-Feb;25(1):25-33
references: 16510354
references: Exp Clin Endocrinol Diabetes. 2005 May;113(5):292-7
references: 15926116
references: Horm Metab Res. 2005 Nov;37(11):702-7
references: 16308840
references: Circulation. 2003 Feb 4;107(4):636-42
references: 12566379
references: Diabet Med. 1999 Sep;16(9):716-30
references: 10510947
references: Diabetes Care. 2006 Jan;29 Suppl 1:S4-42
references: 16373931
references: Diabetes Care. 2000 Apr;23 Suppl 2:B21-9
references: 10860187
references: JAMA. 1999 Jun 2;281(21):2005-12
references: 10359389
references: N Engl J Med. 1996 Mar 21;334(12):777-83
references: 8592553
references: Diabetes Care. 1998 Oct;21(10):1726-31
references: 9773738
references: Diabetes Care. 1990 Jun;13(6):610-30
references: 2192847
references: Horm Metab Res. 1998 Mar;30(3):123-9
references: 9566852
references: Diabetes Care. 2006 Dec;29(12):2644-9
references: 17130198
references: Diabetes. 1994 Mar;43(3):396-402
references: 8314011
references: N Engl J Med. 2002 Feb 7;346(6):393-403
references: 11832527
references: Diabetes. 1995 Nov;44(11):1249-58
references: 7589820
references: BMJ. 2000 Aug 12;321(7258):405-12
references: 10938048